A Study for HSK44459 in Participants With Atopic Dermatitis

PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

January 20, 2026

Study Completion Date

March 23, 2026

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG

HSK44459

HSK44459 will be administered orally twice daily

DRUG

Placebo

Placebo will be administered orally twice daily

Trial Locations (1)

RECRUITING

Affiliated Dermatology Hospital of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Xizang Haisco Pharmaceutical Co., Ltd

INDUSTRY

NCT06996912 - A Study for HSK44459 in Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter